- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1625KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 539KB)
Ixazomib – November 2020
Ixazomib: Capsule 2.3 mg, Capsule 3 mg, Capsule 4 mg; Ninlaro®
Last updated
19 March 2021